eCite Digital Repository

Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease

Citation

Fassett, RG and Robertson, IK and Ball, MJ and Geraghty, DP and Coombes, JS, Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease, Clinical Nephrology, 81, (2) pp. 75-85. ISSN 0301-0430 (2014) [Refereed Article]


Preview
PDF
Restricted - Request a copy
430Kb
  

Copyright Statement

Copyright 2014 Dustri-Verlag Dr K. Feistle

Official URL: http://dx.doi.org/10.1080/00288330.2013.835269

DOI: doi:10.5414/CN108090

Abstract

Background: CKD is associated with increased levels of inflammatory biomarkers.. The effects of atorvastatin on biomarkers of inflammation were assessed in CKD patients.

Methods: One hundred and seventeen patients with serum creatinine > 120 μmol/l were randomized to receive atorvastatin 10 mg/day (56) or placebo (61) and followed for a mean of 2.5 years. Thirty-three individuals with normal kidney function were controls. Outcomes included comparison of changes in pentraxin-3 (PTX3), TNF-α, CRP, IL-6, IL-8 and IL-10 between atorvastatin and placebo-treated patients.

Results: At baseline, compared with controls, CKD patients had increased PTX3 (mean, 1.08 vs 0.58 ng/ml; P < 0.001), CRP (mean, 4.9 vs 1.5 mg/l; P < 0.001), Il-8 (mean, 6.00 vs 4.58 pg/ml; p = 0.001), Il-10 (mean, 59.0 vs 17.6 pg/ml; p = 0.007) and TNF-α (mean, 18.0 vs 5.6 ng/ml; p < 0.001). In patients with raised baseline plasma IL-6/8/10 and/or PTX3 the eGFR decline was significantly less in those treated with atorvastatin compared to placebo (mean change, -3.36; vs +1.25 ml/min/1.73m2/yr; difference, 4.61 95% CI 0.98-8.25; p = 0.002), whilst those without raised inflammatory biomarkers showed no difference. Placebo-treated patients with raised TNF-α levels had no eGFR decline (p = 0.16).

Conclusions: CKD patients had increased biomarkers of inflammation. Those with raised IL-6/8/10 and/or PTX3 at baseline had significantly less eGFR decline when treated with atorvastatin. Atorvastatin may slow eGFR decline in CKD patients with inflammation.

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Clinical Sciences
Research Field:Nephrology and Urology
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Urogenital System and Disorders
Author:Robertson, IK (Dr Iain Robertson)
Author:Ball, MJ (Professor Madeleine Ball)
Author:Geraghty, DP (Professor Dominic Geraghty)
ID Code:86482
Year Published:2014
Web of Science® Times Cited:13
Deposited By:Health Sciences A
Deposited On:2013-09-18
Last Modified:2017-11-02
Downloads:0

Repository Staff Only: item control page